This report analyzes the disruptive themes that have driven M&A activity in Q2 2024 in the pharma Sector.
The global pharma sector in Q2 2024 witnessed deals worth $34 billion, a decline of 38% compared to Q2 2023. In terms of deal volume, there was a decline of 10% to record 227 M&A deals in Q2 2024. The Pharma sector recorded 10 mega deals (defined as any deal valued at more than $1 billion) in Q2 2024, a decrease of 23% compared to Q2 2023.
The global pharma sector in Q2 2024 witnessed deals worth $34 billion, a decline of 38% compared to Q2 2023. In terms of deal volume, there was a decline of 10% to record 227 M&A deals in Q2 2024. The Pharma sector recorded 10 mega deals (defined as any deal valued at more than $1 billion) in Q2 2024, a decrease of 23% compared to Q2 2023.
Scope
- This report provides an overview of merger and acquisition activity globally in Q2 2024 in Pharma Sector
- It identifies the themes driving most notable to deals announced in Q2 2024 in the Pharma Sector
Reasons to Buy
- Companies who invest in the right themes become success stories; those who miss the big themes end up as failures. If you want to understand the themes that drive an industry, simply look at the list of recent mergers and acquisitions (M&A).
- In this report we have listed down the most notable deals in pharma sector to make it easy for our clients to get a view of themes disrupting the sector and prepare for the future.
Table of Contents
- Executive Summary
- Review of Pharma M&A Market - Q2 2024
- Top Pharma M&A Deals by Sector - Q2 2024
- Pharma M&A Deals Analysis by Geography - Q2 2024
- Top Themes Driving Pharma M&A Activity - Q2 2024
- Appendix 1: Deal Selection Criteria
- Appendix 2: Top Themes for 2024 in Pharma
- Appendix 3: Thematic Research Methodology
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Vertex Pharmaceuticals
- Ono Pharmaceutical
- Genmab
- Biogen
- Novartis
- Johnson & Johnson
- Asahi Kasei
- Royalty Pharma
- Johnson & Johnson
- Incyte
- Shanghai Fosun Pharmaceutical
- Harmony Biosciences Holdings
- COVIRIX Medical
- Merck
- Mitsui & Co
- Rohto Pharmaceutical
- Royalty Pharma
- Cycle Pharmaceuticals
- Bruker
- ANI Pharmaceuticals
- Alpine Immune Sciences
- Eyebiotech
- Deciphera Pharmaceuticals
- ProfoundBio US
- Human Immunology Biosciences
- Mariana Oncology
- Yellow Jersey Therapeutics
- Calliditas Therapeutics
- Agios Pharma
- Proteologix
- Escient Pharmaceuticals
- Shanghai Henlius Biotech
- EpyGenix Therapeutics
- NewGenIvf Group
- Mirus Bio
- Eu Yan Sang International
- Sanofi (Frexalimab)
- Vanda Pharmaceuticals
- NanoString Technologies
- Alimera Sciences
